PDCD1 and cancer: Inthis dynamic scenario, the PD-1 mutant, here reported, largely expandsthe chemical space of nonantibody and nonsmall-molecule inhibitortherapeutics that can be used to target cancer cells overexpressingPD-L1 receptors.